tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TSE:MDNA Stock Latest News

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Press ReleasesMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
7d ago
Medicenna’s MDNA11 Shows Promising Trial Results
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promising Trial Results
7d ago
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
PremiumPress Releases
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
7d ago
Medicenna’s Novel Cancer Therapy Shows Promise
PremiumCompany Announcements
Medicenna’s Novel Cancer Therapy Shows Promise
7d ago
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
PremiumPress Releases
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
7d ago
Mayfair Gold Counters Muddy Waters’ Claims
PremiumCompany AnnouncementsMayfair Gold Counters Muddy Waters’ Claims
12d ago
Medicenna Unveils Key Immunotherapy Advances
PremiumCompany Announcements
Medicenna Unveils Key Immunotherapy Advances
1M ago
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
PremiumPress Releases
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
1M ago
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
PremiumPress Releases
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
2M ago
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
PremiumPress Releases
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
2M ago
MDNA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
MDNA Earnings this Week: How Will it Perform?
2M ago
Medicenna Announces Appointment of New Auditor
PremiumPress Releases
Medicenna Announces Appointment of New Auditor
3M ago
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
PremiumPress ReleasesMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
3M ago
Medicenna Extends Period to Exercise Certain Warrants
PremiumPress Releases
Medicenna Extends Period to Exercise Certain Warrants
4M ago
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
PremiumPress Releases
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
4M ago
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
PremiumPress Releases
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
5M ago
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
PremiumPress Releases
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
5M ago
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
PremiumPress Releases
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
5M ago
MDNA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
MDNA Upcoming Earnings Report: What to Expect?
5M ago
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
PremiumPress ReleasesMedicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
5M ago
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
PremiumPress Releases
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
6M ago
MDNA
Medicenna Therapeutics CFO Jeff Caravella, CBO Brent Meadows depart
PremiumThe Fly
Medicenna Therapeutics CFO Jeff Caravella, CBO Brent Meadows depart
6M ago
MDNA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >